GLP-1 peptide tirzepatide: what the clinical evidence shows

Why the dual-receptor action sets tirzepatide apart from earlier GLP-1 medicines

GLP-1 receptor agonists have been used in weight management for several years. They mimic a gut hormone released after eating, slowing gastric emptying and reducing appetite. Tirzepatide does all of that, but it adds a second signal: activation of the GIP receptor, which works through a partly different pathway to reinforce the same outcomes. The two signals together appear to produce a more pronounced reduction in appetite and calorie intake than either alone.

You can read the mechanism explained in plain terms on the NHS tirzepatide page. What the NHS description makes clear is that tirzepatide slows the passage of food through the stomach and acts on appetite centres in the brain, the GIP component adds to both effects. The result, in clinical practice, is that many people find they feel full on considerably less food than before, and interest in eating between meals falls noticeably in the early weeks of treatment.

This is also why the starting dose is set deliberately low. The 2.5mg pen that begins the treatment schedule exists to let the digestive system adjust; nausea and other gastrointestinal effects are most common at the start and after each dose increase, and the gradual titration is designed to limit that. Whether to move to the next dose, and when, is always a prescriber's call based on how you are tolerating the current one.

What the SURMOUNT trial programme found, and what the NICE appraisal concluded

SURMOUNT-1 randomised 2,539 adults with obesity, without type 2 diabetes, to tirzepatide or placebo for 72 weeks. At the 15mg dose, average body-weight reduction was around 20–21%. The 10mg group averaged roughly 19%. Even participants who reduced weight on the lower doses saw clinically meaningful results. The programme as a whole (including the SURPASS diabetes trials) involved more than 10,000 participants across multiple studies, giving regulators and the NHS a substantial evidence base to assess.

NICE reviewed that evidence and published its technology appraisal (TA1026) in December 2024. The committee concluded that tirzepatide is recommended for adults with a BMI of 35 or above and at least one weight-related condition; lower BMI thresholds apply for people from certain ethnic backgrounds under UK clinical guidance. The appraisal also noted that the indirect comparisons in the data favoured tirzepatide over semaglutide 2.4mg, a finding since supported by the SURMOUNT-5 head-to-head trial, in which tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks.

If you want the detailed background on what tirzepatide is as a compound, our tirzepatide peptide page covers the biochemistry and receptor pharmacology in more depth.

Side effects that come with activating these peptide pathways

The side-effect profile follows directly from how the medicine works. Slowing gastric emptying means food sits in the stomach longer, useful for appetite, but it can cause nausea, reflux, burping or a heavy feeling after eating, especially early in treatment or after a dose increase. Constipation and diarrhoea are both reported, sometimes alternating. Fatigue and headache appear in the trials too. For most people these effects are most noticeable in the first week or two at a new dose and then settle.

A January 2026 MHRA Drug Safety Update highlighted acute pancreatitis as an infrequent but serious risk across GLP-1 medicines, and our page on GLP-1 tirzepatide explains how this class of medicine interacts with those receptors and what that means for your risk profile. Severe stomach pain that radiates towards the back, with or without vomiting, warrants urgent medical attention and is not something to wait out. Anyone on tirzepatide can report suspected side effects directly through the MHRA Yellow Card scheme, which exists partly to build the ongoing safety profile of newer medicines like this one.

Injection-site reactions are usually mild and rotate with the site, abdomen, thigh and upper arm are all used. If you are curious about how tirzepatide fits into the broader landscape of GLP therapies and what distinguishes it within that group, that context can be useful when weighing up your options. Storage requires refrigeration; the Patient Information Leaflet gives the exact room-temperature window and should be followed precisely rather than estimated.

Private access through a regulated UK pharmacy versus the NHS route

NHS access to tirzepatide is phased. From June 2025, adults with a BMI of 40 or above and four or more of five specified conditions became eligible; a second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026. GP practices may prescribe under the 2026 QOF contract, but participation varies by practice. If you don't meet the current NHS criteria or simply don't want to wait, private prescription is the legal alternative, and the cost context is worth understanding before you look at prices. Our Mounjaro cost guide sets out what legitimate private treatment includes and why the headline price is rarely the whole picture.

A private route through a GPhC-registered pharmacy works differently from an NHS referral. There is no waiting list. A clinical consultation is completed online; a prescriber reads the responses and supporting information the same day. At nume, that review is carried out by a GPhC-registered Independent Prescriber, a real clinician, not an automated screening tool. Identity and weight are verified directly. Orders placed before 12pm on a weekday and approved that day are dispatched the same afternoon and arrive the following working day with DPD, in plain packaging. That's the kind of turnaround that matters when you've already spent weeks researching and want to start promptly.

Tirzepatide is licensed in the UK as Mounjaro, and if you'd like to understand more about how tirzepatide works as a peptide before your consultation, that background can help you ask more informed questions of your prescriber. For a full overview of the medicine (how it is supplied, what the pen schedule looks like, and who the prescribing criteria apply to) our Mounjaro guide covers each of those questions in detail. For a broader look at which treatments may suit your situation, the weight-loss treatment overview is a useful starting point before a consultation.